Hugh Gemmell1, Axel Hilland. 1. Anglo-European College of Chiropractic, 13-15 Parkwood Road, Bournemouth, BH5 2DF, UK. hgemmell@aecc.ac.uk
Abstract
OBJECTIVE: The purpose of this study was to investigate the immediate effect of electric point stimulation in treating latent upper trapezius trigger points compared to placebo. DESIGN: Double blind randomised placebo-controlled trial. SETTING: Anglo-European College of Chiropractic. PARTICIPANTS: Sixty participants with latent upper trapezius trigger points. INTERVENTIONS:Electric point stimulator type of TENS, or detuned (inactive) electric point stimulator type of TENS. MAIN OUTCOME MEASURES: The three outcome measures were pressure pain threshold at the trigger point, a numerical rating scale for pain elicited over the trigger point, and lateral cervical flexion to the side opposite the trigger point. RESULTS: On the outcome of pressure pain threshold the electric point stimulator group had a mean change of 0.49 (0.99) kg/cm(2), while the placebo group had a mean change of 0.45 (0.98) kg/cm(2) (t = 0.16, df = 58, p = 0.88). For change in pain over the trigger point, the electric point stimulator group had a mean decrease of 0.93 (0.87) points, while the placebo group had a mean decrease of 0.23 (0.97) points (t = 0.70, df = 58, p = 0.005). On the outcome of change in lateral cervical flexion the electric point stimulator group had a mean increase of 2.87 (4.55) degrees, while the placebo group had a mean increase of 1.99 (2.49) degrees (t = 0.92, df = 58, p = 0.36). CONCLUSION: Electric point stimulator type of TENS is superior to placebo only in reduction of pain for treating latent upper trapezius trigger points.
RCT Entities:
OBJECTIVE: The purpose of this study was to investigate the immediate effect of electric point stimulation in treating latent upper trapezius trigger points compared to placebo. DESIGN: Double blind randomised placebo-controlled trial. SETTING: Anglo-European College of Chiropractic. PARTICIPANTS: Sixty participants with latent upper trapezius trigger points. INTERVENTIONS: Electric point stimulator type of TENS, or detuned (inactive) electric point stimulator type of TENS. MAIN OUTCOME MEASURES: The three outcome measures were pressure pain threshold at the trigger point, a numerical rating scale for pain elicited over the trigger point, and lateral cervical flexion to the side opposite the trigger point. RESULTS: On the outcome of pressure pain threshold the electric point stimulator group had a mean change of 0.49 (0.99) kg/cm(2), while the placebo group had a mean change of 0.45 (0.98) kg/cm(2) (t = 0.16, df = 58, p = 0.88). For change in pain over the trigger point, the electric point stimulator group had a mean decrease of 0.93 (0.87) points, while the placebo group had a mean decrease of 0.23 (0.97) points (t = 0.70, df = 58, p = 0.005). On the outcome of change in lateral cervical flexion the electric point stimulator group had a mean increase of 2.87 (4.55) degrees, while the placebo group had a mean increase of 1.99 (2.49) degrees (t = 0.92, df = 58, p = 0.36). CONCLUSION: Electric point stimulator type of TENS is superior to placebo only in reduction of pain for treating latent upper trapezius trigger points.
Authors: Jose V León-Hernández; Aitor Martín-Pintado-Zugasti; Laura G Frutos; Isabel M Alguacil-Diego; Ana I de la Llave-Rincón; Josue Fernandez-Carnero Journal: Braz J Phys Ther Date: 2016-07-11 Impact factor: 3.377
Authors: Ana Paula de Lima Ferreira; Dayse Regina Alves da Costa; Ana Izabela Sobral de Oliveira; Elyson Adam Nunes Carvalho; Paulo César Rodrigues Conti; Yuri Martins Costa; Leonardo Rigoldi Bonjardim Journal: J Appl Oral Sci Date: 2017 Mar-Apr Impact factor: 2.698
Authors: Ana Luiza C Martimbianco; Gustavo Jm Porfírio; Rafael L Pacheco; Maria Regina Torloni; Rachel Riera Journal: Cochrane Database Syst Rev Date: 2019-12-12
Authors: Tomasz Halski; Kuba Ptaszkowski; Lucyna Słupska; Małgorzata Paprocka-Borowicz; Robert Dymarek; Jakub Taradaj; Gabriela Bidzińska; Daniel Marczyński; Aleksandra Cynarska; Joanna Rosińczuk Journal: Evid Based Complement Alternat Med Date: 2015-09-29 Impact factor: 2.629